UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2072) 2072
science & technology (1848) 1848
life sciences & biomedicine (1743) 1743
dacarbazine - analogs & derivatives (1696) 1696
dacarbazine - pharmacology (1360) 1360
oncology (1166) 1166
temozolomide (932) 932
cell line, tumor (874) 874
animals (841) 841
male (822) 822
female (814) 814
dacarbazine - administration & dosage (649) 649
antineoplastic agents, alkylating - pharmacology (643) 643
mice (583) 583
dacarbazine - therapeutic use (562) 562
brain neoplasms - drug therapy (544) 544
adult (524) 524
middle aged (518) 518
chemotherapy (470) 470
glioblastoma - drug therapy (469) 469
cancer (413) 413
aged (408) 408
antineoplastic combined chemotherapy protocols - therapeutic use (407) 407
glioblastoma (401) 401
pharmacology & pharmacy (398) 398
brain neoplasms - pathology (380) 380
apoptosis - drug effects (358) 358
antineoplastic agents - pharmacology (351) 351
glioblastoma - pathology (337) 337
apoptosis (319) 319
cell proliferation - drug effects (301) 301
antineoplastic agents, alkylating - therapeutic use (294) 294
glioma - drug therapy (286) 286
treatment outcome (285) 285
melanoma - drug therapy (261) 261
glioblastoma multiforme (254) 254
drug synergism (244) 244
dacarbazine (243) 243
glioma - pathology (241) 241
cell survival - drug effects (239) 239
drug resistance, neoplasm (234) 234
cell biology (232) 232
dacarbazine - adverse effects (232) 232
gliomas (232) 232
tumors (231) 231
glioma (229) 229
glioblastoma - metabolism (228) 228
xenograft model antitumor assays (220) 220
melanoma (216) 216
brain neoplasms - metabolism (215) 215
dose-response relationship, drug (198) 198
glioblastoma - genetics (195) 195
brain neoplasms - genetics (194) 194
combined modality therapy (194) 194
mice, nude (194) 194
analysis (192) 192
tumor cells, cultured (183) 183
antineoplastic agents (175) 175
adolescent (173) 173
antineoplastic agents, alkylating - administration & dosage (169) 169
neurosciences & neurology (168) 168
brain tumors (167) 167
melanoma - pathology (162) 162
antineoplastic agents - therapeutic use (161) 161
research (159) 159
care and treatment (158) 158
antineoplastic combined chemotherapy protocols - adverse effects (156) 156
brain cancer (156) 156
antimitotic agents (153) 153
cancer therapies (153) 153
doxorubicin - administration & dosage (150) 150
antineoplastic combined chemotherapy protocols - pharmacology (149) 149
dna damage (147) 147
dna repair (147) 147
medicine & public health (147) 147
glioma - metabolism (145) 145
health aspects (141) 141
medicine, research & experimental (137) 137
research & experimental medicine (137) 137
gene expression (134) 134
disease-free survival (133) 133
prognosis (132) 132
drug resistance, neoplasm - drug effects (130) 130
survival analysis (129) 129
rats (128) 128
gene expression regulation, neoplastic - drug effects (127) 127
time factors (126) 126
hodgkin disease - drug therapy (125) 125
biochemistry & molecular biology (124) 124
dna methylation (123) 123
clinical neurology (122) 122
gene expression regulation, neoplastic (121) 121
glioma - genetics (121) 121
proteins (118) 118
antineoplastic combined chemotherapy protocols - administration & dosage (116) 116
research article (115) 115
cytotoxicity (114) 114
bleomycin - administration & dosage (113) 113
drug resistance (113) 113
drug administration schedule (112) 112
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2423) 2423
Japanese (14) 14
Chinese (8) 8
French (6) 6
Italian (6) 6
German (4) 4
Russian (3) 3
Spanish (3) 3
Hungarian (2) 2
Norwegian (2) 2
Polish (2) 2
Czech (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 1/2015, Volume 75, Issue 1, pp. 131 - 141
Neuroblastoma (NB) is one of the most common and deadly pediatric solid tumors. NB is characterized by clinical heterogeneity, from spontaneous regression to... 
Signaling | TrkB | Medicine & Public Health | Oncology | Cancer Research | Neuroblastoma | Pharmacology/Toxicology | Growth inhibition | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Receptor, trkB | Dacarbazine - adverse effects | Membrane Glycoproteins - metabolism | Protein-Tyrosine Kinases - metabolism | Humans | Drugs, Investigational - therapeutic use | Half-Life | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Membrane Glycoproteins - antagonists & inhibitors | Camptothecin - administration & dosage | Antineoplastic Agents - pharmacokinetics | Phosphorylation - drug effects | Camptothecin - analogs & derivatives | Protein Kinase Inhibitors - pharmacokinetics | Cell Survival - drug effects | Dacarbazine - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Mice, Nude | Survival Analysis | Cell Line, Tumor | Neuroblastoma - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drugs, Investigational - pharmacology | Dacarbazine - therapeutic use | Drugs, Investigational - pharmacokinetics | Neuroblastoma - blood | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Proteins - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Protein Processing, Post-Translational - drug effects | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Antineoplastic Agents - pharmacology | Neuroblastoma - pathology | Camptothecin - adverse effects | Camptothecin - therapeutic use | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Neuroblastoma - drug therapy | Drugs, Investigational - administration & dosage | Protein Kinase Inhibitors - pharmacology | Camptothecin - pharmacology | Chemotherapy | Muscle proteins | Growth | Analysis | Cancer | Index Medicus | neuroblastoma | signaling | growth inhibition
Journal Article
Journal Article
Journal Article
Cell stem cell, ISSN 1934-5909, 03/2009, Volume 4, Issue 3, pp. 226 - 235
In normal brain, the side population (SP) phenotype is generated by ABC transporter activity and identifies stem cell and endothelial cell subpopulations by... 
STEMCELL | Cell & Tissue Engineering | Life Sciences & Biomedicine | Science & Technology | Cell Biology | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Neoplastic Stem Cells - drug effects | Humans | Antineoplastic Agents, Alkylating - pharmacology | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | Neoplasm Proteins - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Glioma - metabolism | Brain - metabolism | Neoplastic Stem Cells - metabolism | Dacarbazine - pharmacology | Glioma - pathology | Dacarbazine - analogs & derivatives | ATP-Binding Cassette Transporters - metabolism | Neoplastic Stem Cells - pathology | Antineoplastic Agents - pharmacology | Chromones - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | PTEN Phosphohydrolase - genetics | Cells, Cultured | Dacarbazine - metabolism | Enzyme Inhibitors - pharmacology | Glioma - chemically induced | Morpholines - pharmacology | PTEN Phosphohydrolase - metabolism | Platelet-Derived Growth Factor - pharmacology | Blood-Brain Barrier - metabolism | Animals | Mice, Nude | Brain - pathology | Mice | Mitoxantrone - pharmacology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Antineoplastic Agents, Alkylating - metabolism | Index Medicus | PTEN | Akt | Glioma | Side Population | ABCG2
Journal Article
Drug design, development and therapy, ISSN 1177-8881, 12/2012, Volume 6, pp. 391 - 405
The purpose of this study is to review the development of BRAF inhibitors, with emphasis on the trials conducted with dabrafenib (GSK2118436) and the evolving... 
Vemurafenib | BRAF inhibitor | Clinical trial | GSK1120212 | GSK2118436 | BRAF mutation | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - therapeutic use | Antineoplastic Agents - therapeutic use | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Drug Design | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Imidazoles - therapeutic use | Skin Neoplasms - pathology | Imidazoles - adverse effects | Clinical Trials as Topic | Imidazoles - pharmacology | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Indoles - adverse effects | Sulfonamides - therapeutic use | Melanoma - drug therapy | Oximes - pharmacology | Sulfonamides - adverse effects | Indoles - therapeutic use | Chemotherapy, Combination | Care and treatment | Gene mutations | Melanoma | Research | Drug therapy | Observations | Cancer | Brain | Squamous cell carcinoma | Toxicity | MEK inhibitors | Clinical trials | MAP kinase | Metastasis | Kinases | Patients | Fever | Metastases | Proteins | Dacarbazine | Signal transduction | Chemotherapy | Protein kinase | New combinations | Response rates | Mutation | Genotypes | Index Medicus | clinical trial | vemurafenib
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 03/2007, Volume 6, Issue 3, pp. 945 - 956
Journal Article